HUE055873T2 - Arany klaszter (AuCs) vagy AuCs-t tartalmazó anyagok alkalmazása glaukóma megelõzésére és/vagy kezelésére szolgáló gyógyszer elõállítására - Google Patents
Arany klaszter (AuCs) vagy AuCs-t tartalmazó anyagok alkalmazása glaukóma megelõzésére és/vagy kezelésére szolgáló gyógyszer elõállításáraInfo
- Publication number
- HUE055873T2 HUE055873T2 HUE17873826A HUE17873826A HUE055873T2 HU E055873 T2 HUE055873 T2 HU E055873T2 HU E17873826 A HUE17873826 A HU E17873826A HU E17873826 A HUE17873826 A HU E17873826A HU E055873 T2 HUE055873 T2 HU E055873T2
- Authority
- HU
- Hungary
- Prior art keywords
- gold cluster
- drug
- preventing
- preparation
- containing substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6941—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a granulate or an agglomerate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Ceramic Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611062360 | 2016-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE055873T2 true HUE055873T2 (hu) | 2022-01-28 |
Family
ID=62194814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE17873826A HUE055873T2 (hu) | 2016-11-28 | 2017-11-27 | Arany klaszter (AuCs) vagy AuCs-t tartalmazó anyagok alkalmazása glaukóma megelõzésére és/vagy kezelésére szolgáló gyógyszer elõállítására |
Country Status (11)
Country | Link |
---|---|
US (3) | US11413355B2 (hu) |
EP (1) | EP3545948B1 (hu) |
JP (2) | JP7032616B2 (hu) |
CN (2) | CN108113997B (hu) |
AU (1) | AU2017366624B2 (hu) |
DK (1) | DK3545948T3 (hu) |
ES (1) | ES2886943T3 (hu) |
HK (1) | HK1250486A1 (hu) |
HU (1) | HUE055873T2 (hu) |
PT (1) | PT3545948T (hu) |
WO (1) | WO2018095429A1 (hu) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018095429A1 (zh) * | 2016-11-28 | 2018-05-31 | 深圳深见医药科技有限公司 | 金团簇或含金团簇的物质在制备预防和/或治疗青光眼药物中的应用 |
AU2019423049C1 (en) * | 2019-01-16 | 2023-08-31 | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. | Copper nanoclusters, thymine-modified hyaluronic acid and poly (copper nanoclusters), method for preparing the same, and application thereof |
TWI801618B (zh) * | 2019-06-27 | 2023-05-11 | 晶碩光學股份有限公司 | 具有抗氧化功能的隱形眼鏡產品 |
TWI759610B (zh) * | 2019-06-27 | 2022-04-01 | 晶碩光學股份有限公司 | 具有角膜修護功能的眼用產品 |
WO2021072747A1 (en) * | 2019-10-18 | 2021-04-22 | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. | Composition and method for treatment of diabetes |
CN116115637A (zh) * | 2019-10-18 | 2023-05-16 | 深圳深见医药科技有限公司 | 用于治疗糖尿病的组合物和方法 |
KR20220101698A (ko) * | 2019-12-27 | 2022-07-19 | 우한 바스트 컨덕트 사이언스 파운데이션 컴퍼니 리미티드 | 다발성 경화증의 치료를 위한 조성물 및 방법 |
BR112022018594A2 (pt) * | 2020-03-16 | 2022-11-08 | Wuhan Vast Conduct Science Found Co Ltd | Agrupamentos de ouro (aucs), e composição para tratamento de cirrose hepática |
BR112022022845A2 (pt) * | 2020-05-09 | 2022-12-13 | Shenzhen Profound View Pharmaceutical Tech Co Ltd | Tratamento de efeitos adversos causados por antipsicóticos atípicos |
CN114432340B (zh) * | 2020-11-03 | 2023-06-23 | 北京工业大学 | 一种Au与抗凋亡蛋白拮抗肽的复合物制备以及协同诱导肿瘤细胞凋亡的应用 |
US20230364131A1 (en) * | 2020-11-27 | 2023-11-16 | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. | Gold clusters, compositions, and methods for treatment of cerebral ischemic strokes |
CN112509648B (zh) * | 2020-11-27 | 2022-09-09 | 易波 | 一种用于吸持生物组织的亲水界面 |
EP4294338A1 (en) * | 2021-02-19 | 2023-12-27 | La Eye LLC | Staphyloma supporting device and method for modifying the axial length and curvature of an eye |
WO2023137671A1 (en) * | 2022-01-20 | 2023-07-27 | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. | L-n-isobutyryl cysteine (l-nibc) -bound gold cluster au 15 (l-nibc) 13, compositions and applications thereof |
CN116064031A (zh) * | 2022-12-31 | 2023-05-05 | 哈尔滨师范大学 | 聚集诱导发光型金纳米簇的合成及其应用 |
CN116496786B (zh) * | 2023-07-01 | 2023-09-29 | 北京建工环境修复股份有限公司 | 一种钆纳米簇荧光探针及其在环境检测方面的应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3859882B2 (ja) | 1998-09-14 | 2006-12-20 | 株式会社リコー | 新規なオリゴフェロセニレン誘導体及び電気化学的に活性なクラスター薄膜の製造方法 |
US6989007B2 (en) * | 2001-02-21 | 2006-01-24 | Solx, Inc. | Devices and techniques for treating glaucoma |
US8211656B2 (en) * | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
US20170157038A1 (en) * | 2008-11-13 | 2017-06-08 | Gholam A. Peyman | Ophthalmic drug delivery method |
US9314473B2 (en) * | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
CN103006565B (zh) * | 2011-09-28 | 2014-12-10 | 国家纳米科学中心 | 一种纳米颗粒药物组合物及其制备方法 |
BRPI1106368B1 (pt) * | 2011-10-28 | 2020-12-22 | Fundação Educacional De Criciuma - Fucri | colírio para tratamento de processo inflamatório intra-ocular |
EP2970373A1 (en) * | 2013-03-12 | 2016-01-20 | The Board of Trustees of The Leland Stanford Junior University | Methods and compositions for inhibiting the effects of amyloid beta oligomers |
CN105848686A (zh) * | 2013-11-05 | 2016-08-10 | 埃琳娜·莫洛卡诺瓦 | 用于调节受体和离子通道的位置特异性亚型的纳米结构轭合物 |
CN105061561B (zh) * | 2015-07-21 | 2019-03-26 | 天津大学 | 用于抑制β淀粉样蛋白聚集的多肽和多肽功能化的金纳米粒子及制备和应用 |
ITUA20163432A1 (it) * | 2016-05-13 | 2017-11-13 | Fondazione St Italiano Tecnologia | Processo per la preparazione di nanoparticelle cave con un core metallico |
CN106370640B (zh) * | 2016-11-25 | 2019-07-05 | 西南大学 | 碳点-金簇复合荧光纳米探针及其应用 |
WO2018095429A1 (zh) * | 2016-11-28 | 2018-05-31 | 深圳深见医药科技有限公司 | 金团簇或含金团簇的物质在制备预防和/或治疗青光眼药物中的应用 |
US20190374478A1 (en) * | 2016-12-06 | 2019-12-12 | UNIVERSITé LAVAL | Ultrastable Gold Nanoparticles For Drug Delivery Applications And Synthesis Thereof |
-
2017
- 2017-11-27 WO PCT/CN2017/113112 patent/WO2018095429A1/zh unknown
- 2017-11-27 PT PT178738266T patent/PT3545948T/pt unknown
- 2017-11-27 CN CN201711206774.XA patent/CN108113997B/zh active Active
- 2017-11-27 DK DK17873826.6T patent/DK3545948T3/da active
- 2017-11-27 CN CN202010462709.9A patent/CN111588733B/zh active Active
- 2017-11-27 HU HUE17873826A patent/HUE055873T2/hu unknown
- 2017-11-27 US US16/327,322 patent/US11413355B2/en active Active
- 2017-11-27 AU AU2017366624A patent/AU2017366624B2/en active Active
- 2017-11-27 EP EP17873826.6A patent/EP3545948B1/en active Active
- 2017-11-27 JP JP2019527839A patent/JP7032616B2/ja active Active
- 2017-11-27 ES ES17873826T patent/ES2886943T3/es active Active
-
2018
- 2018-08-01 HK HK18109914.4A patent/HK1250486A1/zh unknown
-
2021
- 2021-12-23 JP JP2021209112A patent/JP7361411B2/ja active Active
-
2022
- 2022-06-28 US US17/809,554 patent/US11969477B2/en active Active
-
2024
- 2024-03-27 US US18/619,103 patent/US20240238443A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7361411B2 (ja) | 2023-10-16 |
AU2017366624A1 (en) | 2019-05-02 |
PT3545948T (pt) | 2021-09-10 |
ES2886943T3 (es) | 2021-12-21 |
AU2017366624B2 (en) | 2020-10-08 |
JP7032616B2 (ja) | 2022-03-09 |
US11413355B2 (en) | 2022-08-16 |
CN108113997A (zh) | 2018-06-05 |
US11969477B2 (en) | 2024-04-30 |
CN111588733A (zh) | 2020-08-28 |
JP2020500858A (ja) | 2020-01-16 |
CN111588733B (zh) | 2022-08-12 |
EP3545948A1 (en) | 2019-10-02 |
WO2018095429A1 (zh) | 2018-05-31 |
US20190175753A1 (en) | 2019-06-13 |
EP3545948A4 (en) | 2020-07-08 |
US20240238443A1 (en) | 2024-07-18 |
HK1250486A1 (zh) | 2018-12-21 |
JP2022046625A (ja) | 2022-03-23 |
EP3545948B1 (en) | 2021-08-11 |
US20220323608A1 (en) | 2022-10-13 |
DK3545948T3 (da) | 2021-09-20 |
CN108113997B (zh) | 2020-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3545948T (pt) | Utilização de aglomerado de ouro ou substância que contém aglomerado de ouro na preparação de droga para prevenção e/ou tratamento de glaucoma | |
IL285179A (en) | Pharmaceutical preparations containing synthetic glycans for use in the treatment of diseases of the digestive system and methods and methods for their preparation | |
HK1250487A1 (zh) | 含金團簇的物質在製備預防和治療阿茲海默病藥物中的應用 | |
IL262831A (en) | Medical implants and methods for their preparation | |
IL264301A (en) | Treatment of Fabry disease in ert-naive and ert-experienced patients | |
HUE049237T2 (hu) | Készítmények a bõr sérülései, rendellenességei és betegségei kezelési eljárásaiban történõ alkalmazásra | |
IL287749A (en) | Compositions for administering implantable drugs and methods of their use | |
HK1254909A1 (zh) | 藥物納米粒子的傳送及其使用方法 | |
IL258854A (en) | Preparations containing cannabidiol and secondary medicinal agents for cancer treatment | |
GB201411465D0 (en) | Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer | |
HK1250950A1 (zh) | 曲美他嗪在製備防治肝病的藥物中的用途 | |
EP3169321A4 (en) | Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health | |
EP3337482A4 (en) | TRANSDERMAL FORMULATIONS FOR THE DISTRIBUTION OF BERBERIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF BERBER INDEPENDENT ILLNESSES AND DISORDERS | |
SG11202000423XA (en) | Treatment of fabry disease in ert-naïve and ert-experienced patients | |
IL270159B (en) | Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases | |
HK1257585A1 (zh) | 預防和治療皮膚纖維化的藥物及其用途 | |
EP3553074A4 (en) | VAP POLYPEPTIDE AND USE THEREOF IN THE MANUFACTURING OF A MEDICINAL PRODUCT FOR THE SPECIFIC DIAGNOSIS AND TREATMENT OF A TUMOR | |
HK1243327A1 (zh) | 包含螺旋藻和棕櫚酰基乙醇酰胺和/或其鹽或藥用上可接受衍生物的組合及其製劑,用於預防和/或治療過度活化的組織病症 | |
SG11201704430SA (en) | Preventive and/or therapeutic agent of immune disease | |
IL249860A0 (en) | Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer | |
EP3375445A4 (en) | USE OF AKT2 IN THE DIAGNOSIS AND TREATMENT OF A TUMOR | |
SG11201701939UA (en) | Cosmetic and/or pharmaceutical composition in the form of a dispersion, method for preparing same and use thereof for skin treatment | |
ZA201907334B (en) | Use of berberine or active metabolite thereof in preparation of drug for preventing and/or treating phenylketonuria | |
PT3733190T (pt) | Utilização de composto na preparação de fármaco para tratar doença dos pequenos vasos cerebrais | |
ZA201804198B (en) | Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body |